Skip to main content
. 2014 Jun 6;2(5):827–832. doi: 10.3892/mco.2014.306

Figure 3.

Figure 3

Comparison of second-line progression-free survival (PFS) time (A) between XELIRI and XELIRI + bevacizumab (BV) and (B) second-line PFS in the BBP+ group between patients with a first-line PFS time of ≥3 months (M) and patients with a first-line PFS time <3 M. Any patients in the BBP+ group, regardless of their response in a first-line setting, showed a higher second-line PFS than patients in the BBP− group (broken line). NS, no significance.